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Introduction 
The symposium that never occurred: 
pre-clinical and clinical development of sibenadet 
S. I. RENNARD 
University of Nebraska Medical Center, U.S.A. 
Chronic obstructive pulmonary disease (COPD) is a 
major cause of morbidity and mortality worldwide. Its 
prevalence has risen greatly over the last several decades 
and will continue to rise, becoming the third largest 
cause of death and the fifth largest cause of morbidity by 
the year 2020. It is a relentlessly progressive disorder. 
While current treatments for COPD offer some benefits 
to patients, they do not (with the exception of smoking 
cessation) affect the rate at which lung function is lost 
and they only partially address patient symptoms. 
The following articles describe the results of the 
development programme for a novel dual D 2 dopamine 
receptor, ~2-adrenoceptor agonist, sibenadet (Viozan TM), 
which was specifically developed to address the unmet 
needs of the symptomatic patient with COPD. Although 
the development of sibenadet has been discontinued ue 
to disappointing efficacy findings, this compendium is 
remarkable in a number of respects. 
First, the articles summarize 'symposia that never 
occurred', substituting for both a planned global expert 
roundtable meeting that did not occur due to the 
shocking events of I I September 2001 in NewYork, and 
the congress symposia that would have taken place had 
sibenadet development been continued. AstraZeneca 
has, however, committed the resources to support the 
current supplement. This decision was taken not only 
because of the company commitment to publishing study 
findings, but also due to the recognition that lessons 
learned during the sibenadet development programme 
are important for the future development of medications 
to help the patient with COPD. 
Second, the clinical community concerned with 
COPD was energized and enthusiastically awaiting 
sibenadet. It held promise to be the first medication 
with demonstrated efficacy to improve symptoms of 
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breathlessness, cough and sputum.This triad of cardinal 
symptoms is a major problem for many patients that 
remains unaddressed by any medication. The potential 
to shift the paradigm of COPD treatment and assess- 
ment approaches was therefore apparent. Sibenadet was 
designed to improve breathlessness, cough and sputum 
by means of conventional beta-agonist activity, plus 
inhibition of airway sensory nerve activity through 
activation of dopaminergic receptors.As such, sibenadet 
was aimed at treating an unaddressed dimension in 
COPD. 
Assessing the efficacy of sibenadet required 
approaches not previously used in assessing currently 
available bronchodilators. This necessitated the 
development of a tool to assess the benefit of sibenadet 
on the core COPD symptoms of breathlessness, cough 
and sputum and a novel instrument, the Breathlessness, 
Cough and Sputum Scale (BCSS©), was developed 
specifically for this purpose.The sibenadet development 
programme, therefore, promised a new medication for 
the patient with COPD, assessed using this new 
instrument in addition to more conventional measures. 
Although sibenadet's promise in pre-clinical and early 
clinical trials went unfulfilled, the development 
programme leaves at least two key legacies, i.e. 
knowledge that it is possible to modify COPD symptoms 
with therapeutic intervention and that resultant changes 
can be monitored effectively using the BCSS. In this way 
the BCSS can be used to assess a previously poorly 
evaluated feature of COPD and enable evaluation of 
future therapies. 
A third benefit of this supplement is that the reader 
will be able to track the development story for this novel 
approach from its conceptualization through pre-clinical 
validation, early tests in man and finally to the definitive 
clinical trials.These efforts represent a major investment, 
not only of company resources, but also of the creative 
energies and scientific insights of the investigators 
involved. The reader will be able to observe the 
evidence available when key decisions were made and 
will be able to understand something about how such 
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decisions were made in the face of uncertainty. The 
sibenadet story, therefore, will be of interest to anyone 
concerned with the rational development of novel 
therapies. Thus, while the clinical trials did not 
demonstrate sufficient efficacy for the company to take 
sibenadet forward, the articles presented here are likely 
to be of considerable value to the interested reader. 
Finally, many drugs that fail in development for one 
reason or another do not result in compiled publications 
such as this. AstraZeneca is to be commended for 
recognizing the value of the lessons learned from the 
sibenadet development programme and for helping to 
make them readily accessible through the development 
of this supplement. 
